Herantis Pharma Oyj Past Earnings Performance
Past criteria checks 0/6
Herantis Pharma Oyj has been growing earnings at an average annual rate of 17.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
17.2%
Earnings growth rate
33.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | n/a |
| Return on equity | -30.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Herantis Pharma Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 2 | 0 |
| 31 Mar 24 | 0 | 0 | 2 | 0 |
| 31 Dec 23 | 0 | 0 | 2 | 0 |
| 30 Sep 23 | 0 | -3 | 2 | 0 |
| 30 Jun 23 | 0 | -5 | 2 | 0 |
| 31 Mar 23 | 0 | -7 | 2 | 0 |
| 31 Dec 22 | 0 | -9 | 3 | 0 |
| 30 Sep 22 | 0 | -10 | 3 | 0 |
| 30 Jun 22 | 0 | -10 | 3 | 0 |
| 31 Mar 22 | 0 | -12 | 2 | 0 |
| 31 Dec 21 | 0 | -13 | 2 | 0 |
| 30 Sep 21 | 0 | -13 | 2 | 0 |
| 30 Jun 21 | 0 | -13 | 2 | 0 |
| 31 Mar 21 | 0 | -11 | 2 | 0 |
| 31 Dec 20 | 0 | -9 | 2 | 0 |
| 30 Sep 20 | 0 | -9 | 2 | 0 |
| 30 Jun 20 | 0 | -9 | 2 | 0 |
| 31 Mar 20 | 0 | -9 | 1 | 0 |
| 31 Dec 19 | 0 | -8 | 1 | 0 |
| 30 Sep 19 | 0 | -7 | 1 | 0 |
| 30 Jun 19 | 0 | -6 | 1 | 0 |
| 31 Mar 19 | 0 | -5 | 1 | 0 |
| 31 Dec 18 | 0 | -4 | 1 | 0 |
| 30 Sep 18 | 0 | -3 | 1 | 0 |
| 30 Jun 18 | 0 | -2 | 1 | 0 |
| 31 Mar 18 | 0 | -2 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -3 | 1 | 0 |
| 30 Jun 17 | 0 | -4 | 1 | 0 |
| 31 Mar 17 | 0 | -4 | 1 | 0 |
| 31 Dec 16 | 0 | -4 | 1 | 0 |
| 30 Sep 16 | 0 | -5 | 1 | 0 |
| 30 Jun 16 | 0 | -5 | 1 | 0 |
| 31 Mar 16 | 0 | -11 | 1 | 0 |
| 31 Dec 15 | 0 | -16 | 1 | 0 |
| 30 Sep 15 | 0 | -18 | 1 | 0 |
| 30 Jun 15 | 0 | -19 | 2 | 0 |
| 31 Mar 15 | 0 | -15 | 1 | 0 |
| 31 Dec 14 | 0 | -8 | 1 | 0 |
| 30 Sep 14 | 0 | -6 | 1 | 0 |
| 30 Jun 14 | 0 | -3 | 0 | 0 |
| 31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: HRTIS is currently unprofitable.
Growing Profit Margin: HRTIS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HRTIS is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.
Accelerating Growth: Unable to compare HRTIS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HRTIS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.9%).
Return on Equity
High ROE: HRTIS has a negative Return on Equity (-30.01%), as it is currently unprofitable.